Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ANVS	$1.80	-4.76%	501.65K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ANVS	$1.80	-4.8%	501.65K
3
4
5
6

ANVS

Get Annovis Bio, Inc. Data in Excel

Get Annovis Bio, Inc. Data in Excel